Exposure Pathways of Polystyrene Nanoplastics Mediate Their Cellular Distribution and Toxicity
Abstract
To investigate whether exposure pathways influence the distribution pattern and toxicity of polystyrene nanoplastics (PSNPs) in hepatic cells.
Methods
Male C57BL/6J wild-type healthy mice aged 6 to 8 weeks old and weighed 18 to 22 g were administered with PSNPs via gavage or tail vein injection. Then, we tracked PSNPs distribution in the major organs of mice via an in vivo imaging system (IVIS). After that, we analyzed the cellular accumulation patterns in hepatic cell subpopulations (hepatocytes and Kupffer cells) using immunofluorescence and transmission electron microscopy (TEM). 300 nm PSNPs were administered via gastric gavage or tail vein injection, and 70 nm PSNPs were injected via the portal vein. The cellular localization of PSNPs in the liver was analyzed using immunofluorescence. Subsequently, using AML-12 cells, a normal mouse liver cell line, as the parenchymal hepatocyte model, the uptake of PSNPs in AML-12 cells was analyzed by confocal laser scanning microscope (CLSM). Flow cytometry was performed to observe and quantify PSNPs uptake, and to analyze the underlying endocytosis mechanisms. IVIS was used to analyze PSNPs uptake features in vivo. Finally, using mouse macrophage line RAW264.7 as a Kupffer cell model and AML-12 cells as a parenchymal hepatocyte model, the cell-type-specific toxic effects induced by 100 μg/ml PSNPs were examined through transcriptomics and metabolomics analyses.
Results
IVIS revealed predominant hepatic accumulation of PSNPs regardless of exposure pathways via intragastric gavage or tail vein injection. Immunofluorescence/TEM demonstrated exposure pathway-dependent cellular distribution: intragastric PSNPs were localized mainly in hepatocytes, while intravenous PSNPs were accumulated in Kupffer cells. Changes in particle size (300 nm vs. 70 nm) did not alter the cellular distribution pattern, while 70 nm PSNPs injected via the portal vein accumulated in Kupffer cells, which suggested that the cell-type-specific distribution of PSNPs in the liver was independent of PSNPs size and might be related to the transport of PSNPs in the gastrointestinal tract. Flow cytometry showed that PSNPs uptake by AML-12 was time-dependent and that the underlying endocytosis mechanism involved pathways mediated by clathrin (P < 0.0001), macropinocytosis (P = 0.0026), and lipid rafts (P < 0.0001). Findings on PSNPs distribution in blood revealed that the uptake of PSNPs by hepatocytes exhibited a rate saturation phenomenon. Multi-omics analysis identified distinct toxicity patterns: PSNPs disrupted lipid metabolism and neurotransmitter homeostasis in AML-12 cells and induced inflammation and oxidative stress in Kupffer cells.
Conclusion
Exposure pathways mediate the hepatic cell-type-specific distribution of PSNPs, thereby altering the downstream toxicological consequences induced by exposure to PSNPs.
Keywords: Microplastics, Environmental exposure, Cytotoxicity
Full Text:
PDFReferences
LESLIE H A, Van VELZEN M J M, BRANDSMA S H, et al. Discovery and quantification of plastic particle pollution in human blood. Environ Int, 2022, 163: 107199. doi: 10.1016/j.envint.2022.107199.
LIU Z, SOKRATIAN A, DUDA A M, et al. Anionic nanoplastic contaminants promote parkinson's disease-associated α-synuclein aggregation. Sci Adv, 2023, 9(46): eadi8716. doi: 10.1126/sciadv.adi8716.
MARFELLA R, PRATTICHIZZO F, SARDU C, et al. Microplastics and nanoplastics in atheromas and cardiovascular events. N Engl J Med, 2024, 390(10): 900-910. doi: 10.1056/NEJMoa2309822.
AMATO-LOURENÇO L F, CARVALHO-OLIVEIRA R, JÚNIOR G R, et al. Presence of airborne microplastics in human lung tissue. J Hazard Mater, 2021, 416: 126124. doi: 10.1016/j.jhazmat.2021.126124.
RAGUSA A, SVELATO A, SANTACROCE C, et al. Plasticenta: first evidence of microplastics in human placenta. Environ Int, 2021, 146: 106274. doi: 10.1016/j.envint.2020.106274.
THOMPSON R C, COURTENE-JONES W, BOUCHER J, et al. Twenty years of microplastic pollution research-what have we learned? Science, 2024, 386(6720): eadl2746. doi: 10.1126/science.adl2746.
WINIARSKA E, JUTEL M, ZEMELKA-WIACEK M. The potential impact of nano- and microplastics on human health: understanding human health risks. Environ Res, 2024, 251(Pt 2): 118535. doi: 10.1016/j. envres.2024.118535.
TSOI K M, MACPARLAND S A, MA X Z, et al. Mechanism of hard-nanomaterial clearance by the liver. Nat Mater, 2016, 15(11): 1212-1221. doi: 10.1038/nmat4718.
TREFTS E, GANNON M, WASSERMAN D H. The liver. Curr Biol, 2017, 27(21): 1147-1151. doi: 10.1016/j.cub.2017.09.019.
LI J, CHEN C, XIA T. Understanding nanomaterial-liver interactions to facilitate the development of safer nanoapplications. Adv Mater, 2022, 34(11): e2106456. doi: 10.1002/adma.202106456.
VINKEN M, HENGSTLER J G. Characterization of hepatocyte-based in vitro systems for reliable toxicity testing. Arch Toxicol, 2018, 92(10): 2981-2986. doi: 10.1007/s00204-018-2297-6.
DOU L, SHI X, HE X, et al. Macrophage phenotype and function in liver disorder. Front Immunol, 2019, 10: 3112. doi: 10.3389/fimmu.2019.03112.
SUN X D, YUAN X Z, JIA Y, et al. Differentially charged nanoplastics demonstrate distinct accumulation in arabidopsis thaliana. Nat Nanotechnol, 2020, 15(9): 755-760. doi: 10.1038/s41565-020-0707-4.
LIU B, NGUYEN P L, YU H, et al. Honey vesicle-like nanoparticles protect aged liver from non-alcoholic steatohepatitis. Acta Pharm Sin B, 2024, 14(8): 3661-3679. doi: 10.1016/j.apsb.2024.05.002.
OUYANG B, POON W, ZHANG Y N, et al. The dose threshold for nanoparticle tumour delivery. Nat Mater, 2020, 19(12): 1362-1371. doi: 10.1038/s41563-020-0755-z.
JI G, MA L, YAO H, et al. Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. Acta Pharm Sin B, 2020, 10(11): 2171-2182. doi: 10. 1016/j.apsb.2020.09.004.
XU M, QI Y, LIU G, et al. Size-dependent in vivo transport of nanoparticles: implications for delivery, targeting, and clearance. ACS Nano, 2023, 17(21): 20825-20849. doi: 10.1021/acsnano.3c05853.
ZHANG H, GUO Y, JIAO J, et al. A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging. Nat Biomed Eng, 2023, 7(3): 221-235. doi: 10.1038/s41551-022-00975-2.
XIE D, ZHAO H, LU J, et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling. Am J Physiol Endocrinol Metab, 2021, 320(6): 1032-1043. doi: 10.1152/ajpendo.00518.2020.
ARYAL B, PRICE N L, SUAREZ Y, et al. Angptl4 in metabolic and cardiovascular disease. Trends Mol Med, 2019, 25(8): 723-734. doi: 10. 1016/j.molmed.2019.05.010.
WANG X Y, XU Q B, HE J Q. DUSP8 Overexpression alleviates LPS-induced macrophage inflammatory responses through JNK/p38 MAPK pathways. Chin J Biochem Mol Biol, 2021, 37(2): 229-235. doi: 10.13865/j. cnki.cjbmb.2020.12.1439.
WANG X N, AO Q, HUANG H, et al. Research progress of dual-specificity phosphatase in diabetic nephropathy. Medical Journal of Peking Union Medical College Hospital, 2025, 16(3): 730-738. doi: 10. 12290/xhyxzz.2024-0258.
WANG X X, ZHANG Y, WAN X K, et al. Responsive expression of maff to β-amyloid-induced oxidative stress. Dis Markers, 2020, 2020: 8861358. doi: 10.1155/2020/8861358.
HEUNINCK J, PERPIÑÁ VICIANO C, IŞBILIR A, et al. Context-dependent signaling of Cxc chemokine receptor 4 and atypical chemokine receptor 3. Mol Pharmacol, 2019, 96(6): 778-793. doi: 10.1124/mol.118. 115477.
ZHANG L, WEI W. Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. Pharmacol Ther, 2020, 207: 107452. doi: 10.1016/j.pharmthera.2019.107452.
XIAO Q, ZOULIKHA M, QIU M, et al. The effects of protein corona on in vivo fate of nanocarriers. Adv Drug Deliv Rev, 2022, 186: 114356. doi: 10.1016/j.addr.2022.114356.
EMILSSON G, LIU K, HÖÖK F, et al. The in vivo fate of polycatecholamine coated nanoparticles is determined by a fibrinogen enriched protein corona. ACS Nano, 2023, 17(24): 24725-24742. doi: 10. 1021/acsnano.3c04968.
DING T H, WU E C, ZHAN C Y. In vivo delivery process and regulating mechanisms of lipid-based nanomedicines. Acta Pharm Sin, 2023, 58(8): 2283-2291. doi: 10.16438/j.0513-4870.2023-0453.
TANG H, ZHANG Y, YANG T, et al. Cholesterol modulates the physiological response to nanoparticles by changing the composition of protein corona. Nat Nanotechnol, 2023, 18(9): 1067-1077. doi: 10.1038/s41565-023-01455-7.
WU J, XING L, ZHENG Y, et al. Disease-specific protein corona formed in pathological intestine enhances the oral absorption of nanoparticles. Acta Pharm Sin B, 2023, 13(9): 3876-3891. doi: 10.1016/j.apsb.2023.02.012.
WEN P, KE W, DIRISALA A, et al. Stealth and pseudo-stealth nanocarriers. Adv Drug Deliv Rev, 2023, 198: 114895. doi: 10.1016/j.addr. 2023.114895.
Refbacks
- There are currently no refbacks.



